Business
Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate
SOLANA BEACH, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today commented on the White House’s recent Executive Order establishing a Medicare pilot program to support reimbursement and structured data collection for cannabidiol (CBD) products.
About this update from Artelo Biosciences, Inc.
[{"type":"image","alt":"Artelo Biosciences","displaySize":"","headline":null,"caption":"Artelo Biosciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":183,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/0fcfe43e16f7cfc8e2a0ef70f1c6364e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dtRWcM_YXYcz7bexobLzxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE1NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0fcfe43e16f7cfc8e2a0ef70f1c6364e","width":183,"height":80}},"lazy":false},{"type":"text","content":"SOLANA BEACH, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today commented on the White House’s recent Executive Order establishing a Medicare pilot program to support reimbursement and structured data collection for cannabidiol (CBD) products.","length":500,"tagName":"p"},{"type":"text","content":"Artelo views the Administration’s action as a significant milestone in the recognition of CBD’s therapeutic potential and an important step toward improving access to cannabinoid-based treatments for aging and medically vulnerable populations. The Company believes the federal government’s emphasis on data collection to inform future research and potential expansion to Medicaid and broader patient populations highlights a growing demand for safe, effective, and well-characterized CBD therapies.","length":498,"tagName":"p"},{"type":"text","content":"“This Executive Order represents meaningful validation of medical CBD and reinforces the need to pair expanded access with rigorous science,” said Gregory D. Gorgas, Chief Executive Officer of Artelo. “Physicians and patients need standardized dosing, consistent pharmacokinetics, and clinical evidence that distinguishes true therapeutic candidates from consumer-grade wellness products.”","length":389,"tagName":"p"},{"type":"text","content":"Artelo believes the initiative highlights an urgent need for well-controlled, peer-reviewed clinical studies to establish the safety, efficacy, and reliability of CBD-based treatments. While consumer CBD products are widely available, many lack the consistency, bioavailability, and qualit...